- Home
- Software Solutions
- Resources
- Corporate
News feeds from around the industry (Updated Hourly) - Updated on June 19, 2013
b3c newswire
>AOP Orphan Spins Off Its Stake in Activartis and Outlines Business Strategy
>Roche's Rapid Mycoplasma Detection Test MycoTOOL Receives Acceptance from Canadian ...
>As the First Biopharmaceutical Company Worldwide, apceth Receives Approval for a Clinical Trial ...
>ExpreS2ion Biotechnologies and the Protein Purification Facility at Cancer Research UK's ...
>Roche Launches New Software Updates for Its LightCycler 96 and LightCycler Nano PCR Systems
>AOP Orphan Spins Off Its Stake in Activartis and Outlines Business Strategy
>Roche's Rapid Mycoplasma Detection Test MycoTOOL Receives Acceptance from Canadian ...
>As the First Biopharmaceutical Company Worldwide, apceth Receives Approval for a Clinical Trial ...
>ExpreS2ion Biotechnologies and the Protein Purification Facility at Cancer Research UK's ...
>Roche Launches New Software Updates for Its LightCycler 96 and LightCycler Nano PCR Systems
BioSpace
>Alexion Pharmaceuticals Inc. to Break Ground on $100 Million Headquarters, Will Create 200-300 New Jobs
>FDA Probes Deaths of Two Patients on Eli Lilly and Company Schizophrenia Drug
>Supreme Court Tells FTC and Drug Industry to Go to War
>Red-Meat Eaters Increase Risk of Diabetes With More Portions, Reveals
>Paper Towels Better for Hand Hygiene Than Electric Dryers, Queensland University of Technology Study
>Alexion Pharmaceuticals Inc. to Break Ground on $100 Million Headquarters, Will Create 200-300 New Jobs
>FDA Probes Deaths of Two Patients on Eli Lilly and Company Schizophrenia Drug
>Supreme Court Tells FTC and Drug Industry to Go to War
>Red-Meat Eaters Increase Risk of Diabetes With More Portions, Reveals
>Paper Towels Better for Hand Hygiene Than Electric Dryers, Queensland University of Technology Study
BioSpace - Breaking News
>Vanda Pharmaceuticals, Inc. Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm in Blind Patients With Non-24-Hour Disorder
>Ipsen Release: "PRIMARYS" Study Investigators Observed Clinically Relevant Results in an Investigational Phase III Study With Somatuline® Autogel® 120 mg in Patients With Acromegaly
>Adamas Pharmaceuticals Presents Positive Phase 2/3 Results for ADS-5102 for the Treatment of Levodopa-Induced Dyskinesia (LID) in Parkinson's Disease
>Santarus Inc. and Pharming Group Announce FDA Acceptance for Review of RUCONEST (Recombinant Human C1 Esterase Inhibitor) Biologics License Application
>Immune Response BioPharma to Seek Approval of REMUNE With of South Africa
>Vanda Pharmaceuticals, Inc. Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm in Blind Patients With Non-24-Hour Disorder
>Ipsen Release: "PRIMARYS" Study Investigators Observed Clinically Relevant Results in an Investigational Phase III Study With Somatuline® Autogel® 120 mg in Patients With Acromegaly
>Adamas Pharmaceuticals Presents Positive Phase 2/3 Results for ADS-5102 for the Treatment of Levodopa-Induced Dyskinesia (LID) in Parkinson's Disease
>Santarus Inc. and Pharming Group Announce FDA Acceptance for Review of RUCONEST (Recombinant Human C1 Esterase Inhibitor) Biologics License Application
>Immune Response BioPharma to Seek Approval of REMUNE With of South Africa
Biotech News - Business Wire
>Samenvatting: Veelbelovende tussentijdse resultaten van thoracoscopische verwijdering van peristente atriale fibrillatie gepresenteerd tijdens vergadering van de Internationale Vereniging voor Minimaal Invasieve Thoraxchirurgie
>Riassunto: Gruppo Sigma-Tau : Una nuova dialisi efficiente e conveniente per pazienti affetti da malattia renale all'ultimo stadio
>bluebird bio Announces Pricing of Initial Public Offering
>Obesity is a Disease: The American Medical Association Agrees with the American Association of Clinical Endocrinologists
>Le Groupe Sigma-Tau: une nouvelle dialyse efficace et rentable pour les patients souffrant d'insuffisance rénale au stade ultime
>Samenvatting: Veelbelovende tussentijdse resultaten van thoracoscopische verwijdering van peristente atriale fibrillatie gepresenteerd tijdens vergadering van de Internationale Vereniging voor Minimaal Invasieve Thoraxchirurgie
>Riassunto: Gruppo Sigma-Tau : Una nuova dialisi efficiente e conveniente per pazienti affetti da malattia renale all'ultimo stadio
>bluebird bio Announces Pricing of Initial Public Offering
>Obesity is a Disease: The American Medical Association Agrees with the American Association of Clinical Endocrinologists
>Le Groupe Sigma-Tau: une nouvelle dialyse efficace et rentable pour les patients souffrant d'insuffisance rénale au stade ultime
Biotech News - PR Newswire
>Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock
>China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013
>Whirlscape releases Minuum keyboard beta to early users
>Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma
>Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy
>Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock
>China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013
>Whirlscape releases Minuum keyboard beta to early users
>Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma
>Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy
Biotechnology - Moreover
>Analysis of Relative Performance in the Biotechnology Industry for Shares of Incyte (INCY, ONXX, ALKS, SPPI, MITI)
>Top 5 Companies in the Biotechnology Industry with the Best Relative Performance (CPHD, IMGN, HGSI, SGEN, RIGL)
>NIH Translational Center Should ?Raise All Boats,? BIO Says
>Immunogen, inc. reports second quarter fiscal year 2012 financial results and provides quarterly update
>Biotechnology to be 21st-century industry: Life Tech CEO
>Analysis of Relative Performance in the Biotechnology Industry for Shares of Incyte (INCY, ONXX, ALKS, SPPI, MITI)
>Top 5 Companies in the Biotechnology Industry with the Best Relative Performance (CPHD, IMGN, HGSI, SGEN, RIGL)
>NIH Translational Center Should ?Raise All Boats,? BIO Says
>Immunogen, inc. reports second quarter fiscal year 2012 financial results and provides quarterly update
>Biotechnology to be 21st-century industry: Life Tech CEO
Burrill Report
>NIH Expands Repurposing Efforts with New Grants
>AMA Says Obesity Is a Disease
>Elan Shareholders Vote to Nix Royalty Pharma Takeover
>SCOTUS Rules Pay-For-Delay Settlements Can Violate Antitrust Laws
>J&J Bets up to $1 Billion in Aragon Buy
>NIH Expands Repurposing Efforts with New Grants
>AMA Says Obesity Is a Disease
>Elan Shareholders Vote to Nix Royalty Pharma Takeover
>SCOTUS Rules Pay-For-Delay Settlements Can Violate Antitrust Laws
>J&J Bets up to $1 Billion in Aragon Buy
CenterWatch - Clinical Trials
>Sanofi's $20 billion Genzyme buy could fuel a big pharma-biotechnology acquisition trend
>New Quintiles initiative saves investigative sites the time, and cost, of patient recruitment advertising
>Technology companies adapt interactive video concepts for clinical trial informed consent
>CRI buys Lifetree, combining investigative sites on both coasts and across all trial phases
>New $1b NIH center will tackle early-stage drug development to ease industry risk of failure
>Sanofi's $20 billion Genzyme buy could fuel a big pharma-biotechnology acquisition trend
>New Quintiles initiative saves investigative sites the time, and cost, of patient recruitment advertising
>Technology companies adapt interactive video concepts for clinical trial informed consent
>CRI buys Lifetree, combining investigative sites on both coasts and across all trial phases
>New $1b NIH center will tackle early-stage drug development to ease industry risk of failure
Clinical Trials - Business Wire
>STENTYS Self-Apposing® Stent Demonstrates Lowest Mortality Rate Among Large Heart Attack Trials
>Enzo Biochem Schedules Teleconference to Discuss Second Quarter Results on March 13, 2013 at 8:30 AM E.T.
>Research and Markets: Thromboembolism Global Clinical Trials Review, H1, 2013
>RegeneRx Receives Notice of Allowance for 2nd U.S. Heart Patent
>Trevena to present results of TRV027 Phase 2a Study in Patients with Advanced Heart Failure
>STENTYS Self-Apposing® Stent Demonstrates Lowest Mortality Rate Among Large Heart Attack Trials
>Enzo Biochem Schedules Teleconference to Discuss Second Quarter Results on March 13, 2013 at 8:30 AM E.T.
>Research and Markets: Thromboembolism Global Clinical Trials Review, H1, 2013
>RegeneRx Receives Notice of Allowance for 2nd U.S. Heart Patent
>Trevena to present results of TRV027 Phase 2a Study in Patients with Advanced Heart Failure
Clinical Trials - PR Newswire
>New Analysis of World's Premier AIDS Conference Finds Poor Coverage of Populations Most-at-Risk for HIV
>Long-term donor support helps fund cancer breakthrough
>Currently Available Technology Can Transform Treatment and Care of Children With Chronic Diseases, New Report Says
>Eating Peanut Butter/Peanuts at Breakfast Helps Control Hunger and Blood Sugar All Day
>New CISCRP study shows improvements in public perceptions of clinical research and insights into participant experiences
>New Analysis of World's Premier AIDS Conference Finds Poor Coverage of Populations Most-at-Risk for HIV
>Long-term donor support helps fund cancer breakthrough
>Currently Available Technology Can Transform Treatment and Care of Children With Chronic Diseases, New Report Says
>Eating Peanut Butter/Peanuts at Breakfast Helps Control Hunger and Blood Sugar All Day
>New CISCRP study shows improvements in public perceptions of clinical research and insights into participant experiences
CNN Top Stories
>Court document reveals details
>First lady, girls lunch with Bono
>IRS polls contradict key deposition
>Watch ominous tornado near airport
>Real-life 'Goodfellas' home searched
>Court document reveals details
>First lady, girls lunch with Bono
>IRS polls contradict key deposition
>Watch ominous tornado near airport
>Real-life 'Goodfellas' home searched
FDA Drugs- What's New
>FDA Drug Safety Communication: FDA is investigating two deaths following injection of long-acting antipsychotic Zyprexa Relprevv (olanzapine pamoate)
>May 2013: Additions and Deletions to the Drug Product List
>Update on Main Street Family Pharmacy Products: Samples of injectable methylprednisolone acetate test positive for microbial contamination
>CDERLearn
>FDA Drug Safety Communication: FDA approves label changes for zolpidem products, including new dosing and a recommendation to avoid driving the day after Ambien CR use
>FDA Drug Safety Communication: FDA is investigating two deaths following injection of long-acting antipsychotic Zyprexa Relprevv (olanzapine pamoate)
>May 2013: Additions and Deletions to the Drug Product List
>Update on Main Street Family Pharmacy Products: Samples of injectable methylprednisolone acetate test positive for microbial contamination
>CDERLearn
>FDA Drug Safety Communication: FDA approves label changes for zolpidem products, including new dosing and a recommendation to avoid driving the day after Ambien CR use
FDA News - Business Wire
>Synergy Biomedical Launches BioSphere Putty, a Next Generation Bioactive Bone Graft
>Mascoma Announces FDA Favorable Review of its Next Generation Bioengineered Yeast, TransFerm® Yield+
>Santarus and Pharming Announce FDA Acceptance for Review of RUCONEST (Recombinant Human C1 Esterase Inhibitor) Biologics License Application
>InSite Vision Announces Joint Patent Infringement Lawsuit with Merck Against Mylan Pharmaceuticals
>Santarus President & CEO Gerald Proehl Honored as San Diego Ernst & Young Entrepreneur of the Year 2013 in Life Sciences
>Synergy Biomedical Launches BioSphere Putty, a Next Generation Bioactive Bone Graft
>Mascoma Announces FDA Favorable Review of its Next Generation Bioengineered Yeast, TransFerm® Yield+
>Santarus and Pharming Announce FDA Acceptance for Review of RUCONEST (Recombinant Human C1 Esterase Inhibitor) Biologics License Application
>InSite Vision Announces Joint Patent Infringement Lawsuit with Merck Against Mylan Pharmaceuticals
>Santarus President & CEO Gerald Proehl Honored as San Diego Ernst & Young Entrepreneur of the Year 2013 in Life Sciences
FDA Press Releases
>FDA approves a new silicone gel-filled breast implant
>FDA approves Xgeva to treat giant cell tumor of the bone
>FDA approves two drugs, companion diagnostic test for advanced skin cancer
>FDA announces import of injectable nutrition drugs
>FDA clears first blood tracking device that uses Radio Frequency Identification technology
>FDA approves a new silicone gel-filled breast implant
>FDA approves Xgeva to treat giant cell tumor of the bone
>FDA approves two drugs, companion diagnostic test for advanced skin cancer
>FDA announces import of injectable nutrition drugs
>FDA clears first blood tracking device that uses Radio Frequency Identification technology
FDA Vaccines, Blood and Biologics - What's New
>June 7, 2013 Approval Letter - Fluzone Quadrivalent
>Fluzone Quadrivalent
>Kcentra (Prothrombin Complex Concentrate, Human)Approval Letter and Product Labeling, Posted: 4/30/2013
>Kcentra (Prothrombin Complex Concentrate (Human))
>Phlebotomy System 1.0.0
>June 7, 2013 Approval Letter - Fluzone Quadrivalent
>Fluzone Quadrivalent
>Kcentra (Prothrombin Complex Concentrate, Human)Approval Letter and Product Labeling, Posted: 4/30/2013
>Kcentra (Prothrombin Complex Concentrate (Human))
>Phlebotomy System 1.0.0
FierceBiotech
>Bluebird IPO busts out, raises $101M as biotech offerings turn red hot
>Booming Alexion breaks ground on $140M global HQ
>Adamas claims success with new and improved Parkinson's drug
>Analysis: Big Pharma R&D demonstrates a woeful lack of innovation
>R&D cutbacks loom at Millennium's Cambridge ops
>Bluebird IPO busts out, raises $101M as biotech offerings turn red hot
>Booming Alexion breaks ground on $140M global HQ
>Adamas claims success with new and improved Parkinson's drug
>Analysis: Big Pharma R&D demonstrates a woeful lack of innovation
>R&D cutbacks loom at Millennium's Cambridge ops
FierceBiotech IT
>PatientsLikeMe seals CRO deal for online trial recruitment
>GutCheck nabs $4M, aids Pfizer with consumer-research software
>Berkeley professor: Genomic data leaks seem inevitable
>Cancer Research UK mulls multiple video game options
>23andMe seeks consumer boost in long-range data strategy
>PatientsLikeMe seals CRO deal for online trial recruitment
>GutCheck nabs $4M, aids Pfizer with consumer-research software
>Berkeley professor: Genomic data leaks seem inevitable
>Cancer Research UK mulls multiple video game options
>23andMe seeks consumer boost in long-range data strategy
FierceBiotech Research
>Scientists identify new compound that kills drug-resistant TB
>New drug repairs brain connections lost in Alzheimer's
>New genetic mutations found in families with early-onset Alzheimer's
>Breast cancer cell growth thwarted by osteoporosis drug in preclinical studies
>Inovio says H7N9 bird flu vaccine effective in mice
>Scientists identify new compound that kills drug-resistant TB
>New drug repairs brain connections lost in Alzheimer's
>New genetic mutations found in families with early-onset Alzheimer's
>Breast cancer cell growth thwarted by osteoporosis drug in preclinical studies
>Inovio says H7N9 bird flu vaccine effective in mice
FiercePharma
>AstraZeneca homes in on new HQ and research site in Cambridge
>Newly minted Sanofi diabetes med fails to impress German pricing regulators
>FDA probes long-acting Zyprexa safety after 2 patients die
>Charmed by orphan drugs, suitors line up for ViroPharma
>Who wins after SCOTUS pay-for-delay decision? Lawyers
>AstraZeneca homes in on new HQ and research site in Cambridge
>Newly minted Sanofi diabetes med fails to impress German pricing regulators
>FDA probes long-acting Zyprexa safety after 2 patients die
>Charmed by orphan drugs, suitors line up for ViroPharma
>Who wins after SCOTUS pay-for-delay decision? Lawyers
FiercePharma Manufacturing
>GSK recalls Ventolin over glass particle risk
>French plant part of proposed GSK, Aspen deal
>U.K. relents on July deadline for API certifications
>Roselabs taps growth of prefilled syringe in India
>City forecloses on Indiana insulin plant it helped fund
>GSK recalls Ventolin over glass particle risk
>French plant part of proposed GSK, Aspen deal
>U.K. relents on July deadline for API certifications
>Roselabs taps growth of prefilled syringe in India
>City forecloses on Indiana insulin plant it helped fund
FierceVaccines
>HHS weighs H7N9 vaccine stockpiling options
>Gates-backed vaccine slashes African meningitis deaths
>FDA setback sends Dynavax shares tumbling again
>FDA clears Sanofi to compete for 4-in-1 flu vaccine market
>Oral vaccine aims to end dreaded Delhi belly
>HHS weighs H7N9 vaccine stockpiling options
>Gates-backed vaccine slashes African meningitis deaths
>FDA setback sends Dynavax shares tumbling again
>FDA clears Sanofi to compete for 4-in-1 flu vaccine market
>Oral vaccine aims to end dreaded Delhi belly
Health News - BizJournals.com
>Dayton-area assisted living facilities set for renovations
>Scottsdale Health Partners, Cigna team on accountable care initiative
>Duke study reveals key to childhood obesity prevention
>ASU Cronkite School creates program to strengthen medical journalism
>Is your company's employee wellness program ready for 2014?
>Dayton-area assisted living facilities set for renovations
>Scottsdale Health Partners, Cigna team on accountable care initiative
>Duke study reveals key to childhood obesity prevention
>ASU Cronkite School creates program to strengthen medical journalism
>Is your company's employee wellness program ready for 2014?
Health News - CNBC
>Germany's Merck Serono to produce medicines in UAE
>Germany's Merck Serono to produce medicines in UAE
>Analysis: Drugmakers step up search for hearing loss medicines
>Grand jury probing meningitis-linked pharmacy: newspaper
>Small Employers Weigh Impact of Providing Health Insurance
>Germany's Merck Serono to produce medicines in UAE
>Germany's Merck Serono to produce medicines in UAE
>Analysis: Drugmakers step up search for hearing loss medicines
>Grand jury probing meningitis-linked pharmacy: newspaper
>Small Employers Weigh Impact of Providing Health Insurance
Health News - Fox Business
>Employers Grateful for Proposed Tax Breaks, But Still Scared
>Employers Grateful for Proposed Tax Breaks, Still Scared
>Insmed Shares Drop as FDA Halts Study After Rat Test Results
>Week Ahead: A Flood Of 2Q Earnings
>Pfizer Drug Raises Heart Attack Risk: Study
>Employers Grateful for Proposed Tax Breaks, But Still Scared
>Employers Grateful for Proposed Tax Breaks, Still Scared
>Insmed Shares Drop as FDA Halts Study After Rat Test Results
>Week Ahead: A Flood Of 2Q Earnings
>Pfizer Drug Raises Heart Attack Risk: Study
Inside Industry - Gen
>T3D Licenses Drug Candidate from Dara, Repositions It for Alzheimer's
>New CHO Cell Lines on the Horizon for Hisun
>Techne Buys Bionostics for $104M
>Transition Bags $7M from Lilly for Rights to Type 2 Diabetes Candidate
>Consortium Wins $8M for Athera CV Drug PC-mAB
>T3D Licenses Drug Candidate from Dara, Repositions It for Alzheimer's
>New CHO Cell Lines on the Horizon for Hisun
>Techne Buys Bionostics for $104M
>Transition Bags $7M from Lilly for Rights to Type 2 Diabetes Candidate
>Consortium Wins $8M for Athera CV Drug PC-mAB
Marketwire - Pharma and Biotech
>Vijay Viswanathan, MD, PhD, FRCP, Receives American Diabetes Association's Vivian Fonseca Scholar Award
>Novo Nordisk A/S: Federal Circuit Court rules on patent litigation involving Prandin(R) (repaglinide)
>Silver Aiding New Medical Technologies
>American Diabetes Association Announces 73rd Scientific Sessions(R) Press Briefing Schedule
>Trelleborg Sealing Solutions Illustrates Newest Technology for Liquid Silicone Rubber (LSR) Applications at 2013 MD&M East
>Vijay Viswanathan, MD, PhD, FRCP, Receives American Diabetes Association's Vivian Fonseca Scholar Award
>Novo Nordisk A/S: Federal Circuit Court rules on patent litigation involving Prandin(R) (repaglinide)
>Silver Aiding New Medical Technologies
>American Diabetes Association Announces 73rd Scientific Sessions(R) Press Briefing Schedule
>Trelleborg Sealing Solutions Illustrates Newest Technology for Liquid Silicone Rubber (LSR) Applications at 2013 MD&M East
MassBio News
>Supreme Court Rejects Gene Patents
>BioPharm America? 2013 program leads with plenary on drug development pipeline ?The Chameleon Rubik's Cube?
>Acceleron Named to the ?Best Places to Work? List by The Scientist Magazine
>Science Takes Center Stage for Hundreds of MA High School Students
>Governor Patrick & MLSC Announce $100M+ in Capital Grants for Western Mass
>Supreme Court Rejects Gene Patents
>BioPharm America? 2013 program leads with plenary on drug development pipeline ?The Chameleon Rubik's Cube?
>Acceleron Named to the ?Best Places to Work? List by The Scientist Magazine
>Science Takes Center Stage for Hundreds of MA High School Students
>Governor Patrick & MLSC Announce $100M+ in Capital Grants for Western Mass
Medical Pharma - PR Newswire
>House Passage of Pain-Capable Unborn Child Protection Act Conforms Law to Modern Science
>Families of Children with Medically Complex Conditions Hit Capitol Hill to Address Medicaid's Role in Child Health
>Patient Advocate Foundation Receives Prestigious Award For Outstanding Case Management In Healthcare
>Nonin Medical Named Platinum Partner by Tri-anim® Health Services for Second Consecutive Year
>Wise Says Study of Medicare Part D Prescription Drug Market Links Proposed Rebates with Diminished Multiemployer Plan Benefits
>House Passage of Pain-Capable Unborn Child Protection Act Conforms Law to Modern Science
>Families of Children with Medically Complex Conditions Hit Capitol Hill to Address Medicaid's Role in Child Health
>Patient Advocate Foundation Receives Prestigious Award For Outstanding Case Management In Healthcare
>Nonin Medical Named Platinum Partner by Tri-anim® Health Services for Second Consecutive Year
>Wise Says Study of Medicare Part D Prescription Drug Market Links Proposed Rebates with Diminished Multiemployer Plan Benefits
National Center for Biotechnology Information
>NCBI Announcements
>NCBI News
>NLM Catalog New and Noteworthy
>PubMed Central News
>GEO Series Releases
>NCBI Announcements
>NCBI News
>NLM Catalog New and Noteworthy
>PubMed Central News
>GEO Series Releases
Nature Biotechnology
>What price affordable access?
>SGLT2 inhibitors enter crowded diabetes space
>Million veterans sequenced
>Amgen announces oncolytic virus shrinks tumors
>Family offices bolster early-stage financing
>What price affordable access?
>SGLT2 inhibitors enter crowded diabetes space
>Million veterans sequenced
>Amgen announces oncolytic virus shrinks tumors
>Family offices bolster early-stage financing
New York Times- Biotechnology
>After DNA Patent Ruling, Availability of Genetic Tests Could Broaden
>Connecticut Approves Genetic Labeling
>Genetically Engineered Wheat Found in Oregon Field
>Taking a Chance on a Reverse Merger
>Biotech Firms, Billions at Risk, Lobby States to Limit GenericsThe industry’s lobbying effort could blunt new competition to its products and reduce the savings anticipated in the federal health care overhaul.
>After DNA Patent Ruling, Availability of Genetic Tests Could Broaden
>Connecticut Approves Genetic Labeling
>Genetically Engineered Wheat Found in Oregon Field
>Taking a Chance on a Reverse Merger
>Biotech Firms, Billions at Risk, Lobby States to Limit GenericsThe industry’s lobbying effort could blunt new competition to its products and reduce the savings anticipated in the federal health care overhaul.
New York Times- Pharmaceuticals
>Proper Scrutiny for Drug Settlements
>Developing Drugs for Rare Diseases
>A.M.A. Recognizes Obesity as a Disease
>Supreme Court Says Drug Makers Can Be Sued Over ‘Pay-for-Delay’ Deals
>Battle for Elan in Doubt After Share Buyback Plan Is Approved
>Proper Scrutiny for Drug Settlements
>Developing Drugs for Rare Diseases
>A.M.A. Recognizes Obesity as a Disease
>Supreme Court Says Drug Makers Can Be Sued Over ‘Pay-for-Delay’ Deals
>Battle for Elan in Doubt After Share Buyback Plan Is Approved
OnBioVC
>OptiMedica, Corp.: Series E $35M
>iRythm Technologies, Inc.: Series C $1.5M
>Edison Pharmaceuticals, Inc.: Series F $20M
>New Haven Pharmaceuticals, Inc.: Series A $6.6M
>Kiadis Pharma, B.V.: Series D $12.8M
>OptiMedica, Corp.: Series E $35M
>iRythm Technologies, Inc.: Series C $1.5M
>Edison Pharmaceuticals, Inc.: Series F $20M
>New Haven Pharmaceuticals, Inc.: Series A $6.6M
>Kiadis Pharma, B.V.: Series D $12.8M
Outsourcing-Pharma
>Kemwell Talks Expansion and Approvals in India and the US
>TFS Sees Increase in Modularization, Shorter Construction Timelines
>AlpVision's iPhone Tech Offers Authentication in War on Counterfeits
>AMRI Exec Discusses 'New Bar' in FDA Enforcement
>Happy holidays from William Reed Business Media!
>Kemwell Talks Expansion and Approvals in India and the US
>TFS Sees Increase in Modularization, Shorter Construction Timelines
>AlpVision's iPhone Tech Offers Authentication in War on Counterfeits
>AMRI Exec Discusses 'New Bar' in FDA Enforcement
>Happy holidays from William Reed Business Media!
Pharma News - Business Wire
>Riassunto: Gruppo Sigma-Tau : Una nuova dialisi efficiente e conveniente per pazienti affetti da malattia renale all'ultimo stadio
>Walgreens Third Quarter 2013 Earnings Release, Conference Call Scheduled for June 25
>Le Groupe Sigma-Tau: une nouvelle dialyse efficace et rentable pour les patients souffrant d'insuffisance rénale au stade ultime
>Rite Aid Announces Tender Offer and Consent Solicitation
>Rite Aid Prices Upsized Offering of Senior Notes
>Riassunto: Gruppo Sigma-Tau : Una nuova dialisi efficiente e conveniente per pazienti affetti da malattia renale all'ultimo stadio
>Walgreens Third Quarter 2013 Earnings Release, Conference Call Scheduled for June 25
>Le Groupe Sigma-Tau: une nouvelle dialyse efficace et rentable pour les patients souffrant d'insuffisance rénale au stade ultime
>Rite Aid Announces Tender Offer and Consent Solicitation
>Rite Aid Prices Upsized Offering of Senior Notes
Pharma News - PharmiWeb
>BioForward Continues Wisconsin Outreach
>SpineGuard Receives U.S. Patent for PediGuard® Pedicle Screw
>Sigma-Tau Group : A New Efficient and Cost Effective Dialysis for Patients with End Stage Renal Disease
>Cellectis SA Combined General Shareholders? Meeting of June 14, 2013
>Thomas A. Shea Joins EPIRUS Biopharmaceuticals as Chief Financial Officer
>BioForward Continues Wisconsin Outreach
>SpineGuard Receives U.S. Patent for PediGuard® Pedicle Screw
>Sigma-Tau Group : A New Efficient and Cost Effective Dialysis for Patients with End Stage Renal Disease
>Cellectis SA Combined General Shareholders? Meeting of June 14, 2013
>Thomas A. Shea Joins EPIRUS Biopharmaceuticals as Chief Financial Officer
Pharma News - PR Newswire
>Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes
>Valeant Pharmaceuticals Prices Public Offering Of Common Shares
>Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition
>Feosol® Iron Supplements Named #1 Pharmacist Recommended Brand for 2013-2014 by U.S. News & World Report and Pharmacy Times
>Though Vital to Educating Doctors on New Products, Pharma "Med Ed" Groups Working Under Huge Internal & External Constraints
>Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes
>Valeant Pharmaceuticals Prices Public Offering Of Common Shares
>Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition
>Feosol® Iron Supplements Named #1 Pharmacist Recommended Brand for 2013-2014 by U.S. News & World Report and Pharmacy Times
>Though Vital to Educating Doctors on New Products, Pharma "Med Ed" Groups Working Under Huge Internal & External Constraints
Pharmaceutical - Moreover
>: Pharmaceuticals look to cure pipeline concerns
>Drug firms sign up to new tropical disease fight
>Cannabis Science Presents Newest Photographs From 3rd Cancer Patient That Show Cancer Tumors Dying and Areas That Are No
>Micro Labs attracts private equity and pharma interest: VCCircle
>Novartis net dips by 5.3% to Rs.38 crore in Q3
>: Pharmaceuticals look to cure pipeline concerns
>Drug firms sign up to new tropical disease fight
>Cannabis Science Presents Newest Photographs From 3rd Cancer Patient That Show Cancer Tumors Dying and Areas That Are No
>Micro Labs attracts private equity and pharma interest: VCCircle
>Novartis net dips by 5.3% to Rs.38 crore in Q3
PR Leap - Biotech
>CPSI Biotech Welcomes Congressman Reed
>CPSI Biotech Awarded the 2013 Tibbetts Award for Technological Innovation and Impact
>Pearl River, New York, Author Publishes New Book for Children about Mental Illness
>West Chester, PA, Author Publishes "All in Good Time"
>Newly Published Book Details the Attempted Recall of Michigan Governor Granholm
>CPSI Biotech Welcomes Congressman Reed
>CPSI Biotech Awarded the 2013 Tibbetts Award for Technological Innovation and Impact
>Pearl River, New York, Author Publishes New Book for Children about Mental Illness
>West Chester, PA, Author Publishes "All in Good Time"
>Newly Published Book Details the Attempted Recall of Michigan Governor Granholm
PRWeb - Biotechnology
>Nasseo Named 2013 Innovation Challenge Winner by Arizona Commerce...
>DuPont Sponsors National AgriScience Ambassador Academy
>Natural Acne Remedies Through Diet, Probiotic Action Shares New...
>ExakTime Introduces AccountLinx Plus
>RAPS Opens Offices in Singapore and China
>Nasseo Named 2013 Innovation Challenge Winner by Arizona Commerce...
>DuPont Sponsors National AgriScience Ambassador Academy
>Natural Acne Remedies Through Diet, Probiotic Action Shares New...
>ExakTime Introduces AccountLinx Plus
>RAPS Opens Offices in Singapore and China
PRWeb - Pharmaceuticals
>New Drug Delivery Partnering Terms and Agreements Market Study Report...
>Yale Releases the Findings of the Medtronic-Commissioned Infuse Bone...
>Biomet Hip Lawsuit News: Bernstein Liebhard LLP Reports on Latest...
>Healthcare Solutions Appoints Richard Leonardo to Chief Sales Officer
>Mirena Lawsuit News: Bernstein Liebhard LLP Comments on Mounting...
>New Drug Delivery Partnering Terms and Agreements Market Study Report...
>Yale Releases the Findings of the Medtronic-Commissioned Infuse Bone...
>Biomet Hip Lawsuit News: Bernstein Liebhard LLP Reports on Latest...
>Healthcare Solutions Appoints Richard Leonardo to Chief Sales Officer
>Mirena Lawsuit News: Bernstein Liebhard LLP Comments on Mounting...
Scientific American
>Pesticides Spark Broad Biodiversity Loss
>Dog Genetics Spur Scientific Spat
>U.S. Kids Born in Polluted Areas More Likely to Have Autism
>Eye-Tracking Software May Reveal Autism and other Brain Disorders
>Will You or the Grid Control Your Electric Car?
>Pesticides Spark Broad Biodiversity Loss
>Dog Genetics Spur Scientific Spat
>U.S. Kids Born in Polluted Areas More Likely to Have Autism
>Eye-Tracking Software May Reveal Autism and other Brain Disorders
>Will You or the Grid Control Your Electric Car?
Sports - ESPN Basketball
>Baylor's Jackson (knee) can't work out for draft
>Drake F King transfers home to Minnesota
>Georgetown's Whittington has torn left ACL
>Sources: Whittington to miss time with injury
>Former Alabama guard Lacey chooses NC State
>Baylor's Jackson (knee) can't work out for draft
>Drake F King transfers home to Minnesota
>Georgetown's Whittington has torn left ACL
>Sources: Whittington to miss time with injury
>Former Alabama guard Lacey chooses NC State
Sports News - ESPN
>Insider: Methodology for CFB Future Power Rankings
>Lunt: Gundy lifted restrictions, but too late
>Hot Board of uncommitted prospects
>Navy to charge football players in rape case
>RecruitingNation: New ESPN 300 five-stars
>Insider: Methodology for CFB Future Power Rankings
>Lunt: Gundy lifted restrictions, but too late
>Hot Board of uncommitted prospects
>Navy to charge football players in rape case
>RecruitingNation: New ESPN 300 five-stars
Xconomy Life Sciences
>Calysta Energy to Harness Microbes for Bioplastics Maker NatureWorks
>Clovis Oncology Closes $275M Offering Following Two Pivotal Weeks
>Alkermes Spinout, Civitas, Nabs Second Grant From Fox Foundation
>Former Genzyme Exec Talks About His New Role as U-M Innovation Evangelist
>New Ambrx CEO Discusses Latest Deal, with China's Zhejiang Medicine
>Calysta Energy to Harness Microbes for Bioplastics Maker NatureWorks
>Clovis Oncology Closes $275M Offering Following Two Pivotal Weeks
>Alkermes Spinout, Civitas, Nabs Second Grant From Fox Foundation
>Former Genzyme Exec Talks About His New Role as U-M Innovation Evangelist
>New Ambrx CEO Discusses Latest Deal, with China's Zhejiang Medicine
Yahoo Biotech News
>Slow, costly process stymies generic biotech drugs (Reuters)
>Analysis: Slow, costly process stymies generic biotech drugs (Reuters)
>Waves Break Coral Embryo into Identical Twins (LiveScience.com)
>Autoinjector Version of MS Drug Approved (HealthDay)
>Fake Avastin had salt, starch, chemicals: Roche (Reuters)
>Slow, costly process stymies generic biotech drugs (Reuters)
>Analysis: Slow, costly process stymies generic biotech drugs (Reuters)
>Waves Break Coral Embryo into Identical Twins (LiveScience.com)
>Autoinjector Version of MS Drug Approved (HealthDay)
>Fake Avastin had salt, starch, chemicals: Roche (Reuters)